- ‘Welcome to the edge of freedom’: Biden’s boots touch down in DMZ
- Obama: Hole U.S. ‘digging out of’ requires billions more in unemployment benefits
- Obama’s regulatory agenda will cost U.S. economy $143B next year: report
- Patriot Act author on James Clapper: Fire, prosecute him
- Russia P.M. Medvedev: No amnesty for political prisoners
- Michigan GOP Senate hopeful reminds government is the ‘servant’
- Christmas, by Congress: Members mull a 15-cent tax on trees
- U.S. unemployment falls to five-year low of 7 percent; 203K jobs added
- World mourns Nelson Mandela and celebrates his life; burial set for Dec. 15
- Bill O’Reilly reminds: Nelson Mandela ‘was a communist’
Job door revolves despite fed rule
Career official walks thin line
When the publicly traded biodefense company PharmAthene Inc. hired Thomas R. Fuerst as its chief scientific officer in April, executives publicized his work as a senior official in the federal government leading the development and acquisition of vaccines and other products against pandemic flu, smallpox and anthrax.
Mr. Fuerst was appointed shortly after his departure from the Department of Health and Human Services at a time when the Annapolis, Md.-based company was trying hard to sell a new anthrax vaccine to the government, highlighting the so-called “revolving door” in which former senior federal officials land jobs in industries with which they interacted while serving in the government.
Though President Obama enacted new revolving-door ethics rules soon after taking office requiring a two-year “cooling off” period for appointees leaving the government, those regulations apply only to incoming appointees - not to career federal employees such as Mr. Fuerst. He holds a doctoral degree in molecular genetics.
“But, as they say, the devil is in the details, and continued enforcement of any post-government restrictions is required,” he said. “Avoiding all conflicts, including the appearance of a conflict, is essential considering the government’s forthcoming procurement of the next anthrax vaccine.”
Company officials said Mr. Fuerst will not communicate with or petition officials in the Biomedical Advanced Research and Development Authority, an agency within HHS, for one year, though he is free to contact officials in other components within the department. They also say he is complying with all post-employment ethics rules.
HHS officials declined to comment other than to confirm that Mr. Fuerst was not a political appointee but a career civil servant.
Craig Holman, legislative representative for Public Citizen, a Washington watchdog group, said Mr. Fuerst’s hiring poses ethical concerns inside and outside government about “revolving-door abuse” and whether the company is trying to “cash in on Fuerst’s connections in government.”
PharmAthene touted Mr. Fuerst’s work with HHS in an April 5 press release that announced his hiring. In its announcement, the company said Mr. Fuerst would oversee the company’s research and development plans and provide “strategic scientific direction” for PharmAthene.
The company also noted that before joining PharmAthene, Mr. Fuerst worked at HHS as director of vaccines and biologics from 2004 to 2007, then as an HHS senior science and technology adviser until he joined PharmAthene.
“During his tenure at HHS, Dr. Fuerst helped establish the Biomedical Advanced Research and Development Authority (BARDA) and oversaw the planning, implementation and monitoring of medical countermeasure development and acquisition, while managing a budget of approximately $3.0 billion,” the company said in its announcement.
A spokeswoman for PharmAthene said Mr. Fuerst wasn’t involved in any contract awards to the company before he joined it. As an adviser, she said, Mr. Fuerst did not oversee anthrax vaccine development programs for BARDA.
She said the hiring of Mr. Fuerst isn’t unlike the December hiring by one of its competitors, Emergent Biosolutions, of a former top official for the Health Protection Agency in Britain.
“We made a conscious decision to be transparent in the hiring of Dr. Fuerst, as evidenced by our April 5th press release announcing his appointment as PharmAthene’s chief scientific officer and, of course, his further introduction on a wider May 11th conference call” with analysts,” Ms. Jurchison said.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
About the Author
- Solaria? Solyndra? Feds bailed on promising solar company, lawsuit says
- Last call: State Dept. bought $180,000 in liquor before shutdown
- Federal prosecutors drop charges against defendants who disappeared
- Bankrupt energy company probed
- Wage nominee at Labor also works for AFL-CIO
Latest Blog Entries
- Obama: Hole U.S. 'digging out of' requires billions more in unemployment benefits
- Bill OReilly reminds: Nelson Mandela was a communist
- Spike in battlefield deaths linked to restrictive rules of engagement
- 'Hunger Games' delivers Obama's message on income inequality
- Obama tries to calm Israeli fears over Iranian nuke deal 'not based on trust'
- Obama administration issues permits for wind farms to kill more eagles
- U.S. debt jumps a record $328 billion tops $17 trillion for first time
- Rush Limbaugh: Obama trying to make Mandela death about himself
- NAPOLITANO: Pope Francis should be saving souls, not pocketbooks
- Inside China: Nuclear submarines capable of widespread attack on U.S.
Independent voices from the The Washington Times Communities
Get in the middle of all the action inside and outside the boxing ring.
Opinion, analysis, and musings on politics, pop culture, reinvention, and the resultant flotsam and jetsam floating around the right-of-center quadrant of the Left Coast.
The cold hard truth about politics in America today and the state of this once great nation.
Find the latest news and happening that effect those in the Washington D.C., Northern Virginia and Maryland Metro region.
White House pets gone wild!